|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.30 USD | -1.63% |
|
-0.26% | +9.41% |
| 06-29 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 33.3 | +69.74% | 12 | ||||||
| 822.31 | +24.01% | 28 | ||||||
| 287.95 | +22.22% | 19 | ||||||
| 2,052,158.8 | +46.58% | 24 | ||||||
| 96.64 | +14.79% | 16 | ||||||
| 224.45 | +7.37% | 31 | ||||||
| 48.26 | -27.98% | 19 | ||||||
| 112.5 | -1.51% | 22 | ||||||
| 101.33 | +31.46% | 25 | ||||||
| 486.67 | +5.52% | 12 | ||||||
| 104.7 | +26.02% | 22 | ||||||
| 276.56 | +21.15% | 21 | ||||||
| 87.69 | +48.13% | 26 | ||||||
| 458,000 | +44.71% | 5 | ||||||
| 361.67 | -0.49% | 9 | ||||||
| - | - | 61.5 | +20.79% | 1 | ||||
| 14.4 | +61.57% | 12 | ||||||
| 72.5 | +11.01% | 2 | ||||||
| 30.05 | +94.64% | 9 | ||||||
| 80.7 | -10.68% | 10 | ||||||
| Average | 125,673.1 | +25.45% | 16 | ||||||
| Weighted average by Cap. | 225,507.84 | +20.44% | 21 |
- Stock Market
- Stocks
- ZLAB Stock
- Sector Zai Lab Limited
- Sector consensus
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
